Monoclonal Antibody to Insulin Like Growth Factor Binding Protein 1 (IGFBP1)
| Code | Size | Price |
|---|
| MAA052Hu26-20ul | 20uL | £88.00 |
Quantity:
| MAA052Hu26-100ul | 100ul | £164.00 |
Quantity:
| MAA052Hu26-200ul | 200ul | £222.00 |
Quantity:
| MAA052Hu26-1ml | 1ml | £509.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2b Kappa
Antibody Clonality: Monoclonal
Antibody Clone: C1
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Further Information
Alternative Names:
IBP1; AFBP; IGF-BP25; PP12; Placental Protein 12; Amniotic Fluid Binding Protein; Alpha-Pregnancy-Associated Endometrial Globulin; Growth Hormone Independent-Binding Protein
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Insulin Like Growth Factor Binding Protein 1
Potency (Clone Number):
C1
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunofluorescence:5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunofluorescence:5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Insulin Like Growth Factor Binding Protein 1 (IGFBP1) | RPA052Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||